Traductor

25 July 2010

Why the MRC didn´t fund research that led to the birth of the world´s first test tube baby


Thirty-two years ago today, the world’s first baby was born after in vitro fertilisation. However, the work that led to the birth of Louise Brown on 25 July 1978 had to be privately funded after the UK’s Medical Research Council decided in 1971 against providing the Cambridge physiologist Robert Edwards and the Oldham gynaecologist Patrick Steptoe with long-term financial support. Today, an intriguing paper published in Europe’s leading reproductive medicine journal Human Reproduction [1] reveals for the first time the reasoning behind the MRC’s much-criticised decision.

The authors of the research, led by Martin Johnson, Professor of Reproductive Sciences at the University of Cambridge, and funded by the Wellcome Trust, write: “The failure of Edwards’ and Steptoe’s application for long-term support was not simply due to widespread establishment hostility to IVF. It failed, we argue for more complex reasons”.

These reasons included:


A strategic error by Edwards and Steptoe when they declined an invitation from the MRC to join a new, directly funded Clinical Research Centre at Northwick Park Hospital, Harrow. They preferred to ask for long-term grant support at the University of Cambridge, but this meant they had to compete for funding with all the other research projects bidding for MRC support. This was also difficult for Cambridge, which lacked the back-up of an academic Department of Obstetrics and Gynaecology at that time.
Most of the MRC referees who were consulted on the proposal considered, in line with government policy, that it was more important to limit fertility and the growth of Britain’s population than to treat infertility. Treating infertility was seen as experimental research rather than as therapeutic.
Concerns about embryo quality (would babies be born with severe abnormalities?) and patient safety made the referees doubt the wisdom of funding embryo transfer without conducting studies in primates first.
Edwards’ and Steptoe’s high profile in the media antagonised the referees who strongly disapproved of this method of public discussion of the science and ethics of treating infertility.


An additional obstacle for Edwards and Steptoe was that they were seen by the MRC as not being part of the “medical establishment”. In their paper, Prof Johnson and his colleagues write: “Steptoe came from a minor northern hospital, while Edwards, though from Cambridge, was neither medically qualified nor yet a professor.” Edwards had a PhD in developmental genetics from the Institute of Animal Genetics at the University of Edinburgh, then the leading UK centre in the field.

Prof Johnson said: “The MRC’s negative decision on funding of IVF, and their public defence of this decision, had major consequences for Edwards and Steptoe and set MRC policy on IVF research funding for the next eight years. This decision was only reversed after the birth of two healthy babies from seven IVF pregnancies. In its 1978/79 Annual Report, the MRC announced a change of policy and from that time on became a strong and major supporter of research on human IVF and human embryos, although curiously not research follow-up of IVF pregnancies.”

Since then, an estimated 4.3 million babies have been born worldwide with the help of a range of fertility treatments developed since the birth of Louise Brown [2].

Prof Johnson and his colleagues, Sarah Franklin, Matthew Cottingham and Nick Hopwood, spent three years studying the MRC records at the National Archives at Kew in Surrey, and also documents from the Royal College of Obstetricians and Gynaecologists, Addenbrooke’s Hospital, Cambridgeshire County Council and Cambridge University Library. Bob Edwards’ wife, Ruth, gave them access to his private papers, and the researchers also interviewed many of the key players involved in the MRC’s decision in 1971 not to fund the research.

In an accompanying editorial [3], Professor John Biggers from Harvard Medical School (USA), writes: “By taking us back 40 years, the authors have demonstrated the importance of understanding a decision in light of the culture and circumstances at the time the decision was made. Although the grant was rejected, Edwards’ and Steptoe’s visions and persistence have benefited an enormous number of infertile people, both male and female.”

Prof Johnson said: “The story of the MRC’s non-funding of IVF belies the cliché that science ‘races ahead’ of society. Similarly, the standard view, that ethical consideration of bioscience and biomedicine can only ever be reactive, is contradicted by the evidence of extensive ethical debate surrounding the prehistory of clinical IVF – most of it actively stimulated by Edwards himself. Although attitudes to medical scientists in the media have changed significantly since the 1970s, scientists and clinicians engaged in high-profile work still face a dilemma. If they encourage public discussion of their work – which they may see as both necessary to securing support and desirable to ensure full ethical debate – must they inevitably weaken their standing among their peers?

“Finally, our case study questions the myth of two courageous mavericks pitted against a conservative establishment. This myth does capture important elements of truth: Edwards and Steptoe were outsiders and did pioneer—against prevailing wisdom—new ideas, therapies, values, public discourses and ethical thinking. But the process of decision-making was more complex than the myth allows. Our research provides a fuller understanding of what happened at the birth of the IVF revolution.”

Prof Johnson believes that today the decision-making processes involved in awarding funding for projects are more open and transparent, with discussion in the wider community and in the media actively welcomed, as was the case with the two Human Fertilisation and Embryology Acts in 1990 and 2008.

“A continuing problem, however, is more to do with the fact that there are some very fashionable topics that can create a buzz and attract huge research interest and funding, sometimes in disproportionate amounts; then it was fertility limitation, more recently genome sequencing would be an example. This can leave other Cinderella topics languishing in the ashes, with little financial support, even though they might well play an equally, if not more, important role in patient welfare.”

24 July 2010

CGF y ANEFP firman un convenio para la promoción de la educación sanitaria en el autocuidado de la salud

El Consejo General de Colegios Oficiales de Farmacéuticos y la Asociación para el Autocuidado de la Salud (ANEFP) han suscrito un convenio de colaboración para la promoción y el impulso de la educación sanitaria de la población en el uso de los medicamentos no sujetos a prescripción y productos destinados al autocuidado de la salud, con el objetivo de contribuir a garantizar su uso racional y adecuado por los ciudadanos con el asesoramiento y consejo de los farmacéuticos en la oficina de farmacia.

Fruto del acuerdo firmado, el Consejo General de Farmacéuticos promoverá entre Consejos autonómicos, Colegios de Farmacéuticos y colegiados actividades de formación e información para fomentar entre la población el autocuidado de la salud, mediante el asesoramiento en la utilización racional y adecuada de los medicamentos no sujetos a prescripción así como de otros productos destinados al autocuidado de la salud. "El objetivo es avanzar en el uso adecuado de estos medicamentos, y trasladar a la sociedad que, como medicamentos que son, pueden tener efectos indeseados si no son bien utilizados, de ahí la importancia de contar siempre con el asesoramiento de un farmacéutico en la oficina de farmacia", ha señalado Carmen Peña, presidenta del Consejo General de Farmacéuticos.

--Asesoramiento farmacéutico.
Las 21.166 farmacias españolas ofrecen cada día miles de consejos sanitarios relacionados con la dispensación de medicamentos que no requieren prescripción médica. Este hecho pone de manifiesto el papel fundamental que juega la farmacia, como establecimiento sanitario, y el farmacéutico, como experto universitario en el medicamento, a la hora de garantizar una correcta dispensación y seguimiento de todos los medicamentos, precisen o no de receta. "La labor de asesoramiento del farmacéutico es fundamental en todo lo relacionado con el medicamento, pero es más importante si cabe en el caso de los medicamentos que no precisan receta, ya que en la mayoría de las ocasiones es el único profesional sanitario al que accede el usuario, de ahí la importancia de fomentar las actividades recogidas en el convenio suscrito hoy", ha destacado Carmen Peña.

Por su parte ANEFP, para facilitar toda la labor de asesoramiento sanitario que los farmacéuticos realizan en su práctica diaria, promoverá entre sus asociados el envío al Consejo General de Farmacéuticos de la información necesaria y actualizada sobre los medicamentos no sujetos a prescripción y sobre aquellos otros productos de autocuidado, para que el Consejo General de Farmacéuticos pueda elaborar contenidos profesionales en sus sistemas de información - bases de datos, publicaciones, portal en INTERNET -, orientados a los farmacéuticos de oficina de farmacia y al público en general.

Jaume Pey, presidente de ANEFP, ha querido destacar la importancia de este acuerdo, que dará continuidad a la colaboración entre la industria farmacéutica y los profesionales farmacéuticos, con el fin de que los ciudadanos dispongan de toda la información y asesoramiento necesario para desarrollar un autocuidado responsable de su salud. "Hoy renovamos el compromiso que ambas instituciones tenemos con el ciudadano para que, con el consejo farmacéutico y los medicamentos sin receta y productos de autocuidado, puedan dar respuesta a su demanda de participar más activamente en el cuidado de sus sintomatologías menores".

--Base de Datos del Conocimiento Sanitario, Bot PLUS.

El convenio recoge también el compromiso de ambas partes a promover, entre administraciones Sanitarias y entidades sanitarias privadas, que los medicamentos no sujetos a prescripción y otros productos para el autocuidado de la salud, estén también incluidos en todos los programas informáticos de ayuda a la prescripción. Con este fin, reconocen la Base de Datos del Conocimiento Sanitario, BOT Plus, como el sistema de información sobre medicamentos más completo.

Este acuerdo facilitará también en el futuro la puesta en marcha, entre otros, de acciones formativas conjuntas, campañas de educación sanitaria a la población o la convocatoria de premios para impulsar la implicación de los profesionales farmacéuticos en la labores de asesoramiento y consejo a la población en este tipo de medicamentos y productos para el autocuidado de la salud.

Riesgos del contacto excesivo con productos de limpieza


Las mujeres que más utilizan productos de limpieza, como ambientadores o antifúngicos, podrían tener un mayor riesgo de desarrollar cáncer de mama que aquellas que los usan con moderación. Este dato sale de un estudio desarrollado en Estados Unidos por un grupo de investigadores del Instituto Silent Spring.

Todo procede de una encuesta realizada a más de 1.500 mujeres y que se ha publicado recientemente en la revista "Environmental Health". El jefe del estudio fue Julia Brody, que ha explicado como se efectuó la consulta en los distintos estados del país a través del teléfono.

No firm conclusions about HDL cholesterol can be drawn from JUPITER sub-analysis

In the Lancet study, Paul Ridker and colleagues, from Brigham and Women’s Hospital (Boston, MA, USA), undertook a retrospective post-hoc analysis of the JUPITER trial. The results show that if a normal, healthy individual has level of low density lipoprotein (LDL), known as “bad cholesterol”, substantially lowered with a potent statin, then the level of HDL “good cholesterol” in that person no longer bears any relation to the remaining cardiovascular risk.

The original JUPITER trial was designed to answer the critical question of whether rosuvastatin prevents cardiovascular disease among healthy people with normal LDL cholesterol levels, but increased levels of high-sensitivity C-reactive protein, a marker of chronic low level inflammation, considered a new risk factor for cardiovascular events.

The current Lancet study showed that when 17,802 subjects were divided into quartiles of HDL cholesterol concentrations, HDL cholesterol concentrations were inversely related to vascular risk at the end of study for individuals randomised to placebo, with the top quartile having a 46% reduced risk compared to the bottom quartile (p=0.0039). In contrast, however, among those subjects given active treatment with rosuvastatin, vascular risk was calculated to be similar for subjects in both the top and bottom HDL quartiles (p=0.82)

“Although measurement of HDL–cholesterol concentration is useful as part of initial cardiovascular risk assessment, HDL-cholesterol concentrations are not predictive of residual vascular risk among patients treated with potent statin therapy who attain very low concentrations of LDL cholesterol,” the authors of the study conclude.

ESC spokesperson Professor Dan Atar, from Oslo University Hospital, Norway, believes there are dangers in interpreting the study as showing that raising HDL levels produces no beneficial cardiovascular effects. “It’s a matter of statistics. If you’re looking at populations with a very low incidence of cardiovascular events, and then with an intervention of any kind you reduce the risk of events even further, it’s logical that you’ll washout the influence of any other effect. These patients already have achieved such low levels of LDL that no other marker will prevail as a predictor of the few remaining events.”

He added that he had concerns that readers of the paper might not appreciate that more data was needed before the scientific community could make a qualified decision about whether raising HDL levels was beneficial or not. “With subgroup analyses, such as the one presented here, you just can’t make such judgements,” he said.

In fact, previous studies, such as the Helsinki Heart Study and the VA-HIT Study , have been successful in raising HDL and reducing cardiovascular events, using gemfibrozil, however this agent also concomitantly lowers LDL. Additionally, the drug nicacin has been shown to be effective at elevating HDL and reducing cardiovascular morbidity in the Coronary Drug Project Study (5), but this strategy could not easily be implemented into clinical practice due to unpleasant side effects, notably flushing. It is hoped that laropiprant, a novel flushing pathway inhibitor, will overcome this limitation.

A clearer indication of the benefit of raising HDL, Atar added, will come from the ongoing phase III Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE), which has enrolled 25,000 patients to investigate whether the combination of niacin/laropiprant can further reduce the risk for myocardial infarction, stroke and the need for revascularisation in patients already treated to lower LDL.

Los pescados grasos son buenos para la vista


Los adultos mayores que comen pescados grasos, al menos una vez por semana, tienen menos riesgo de desarrollar la DMAE( Degeneración Macular asociada a la edad). Los resultados de un estudio, publicado recientemente en la revista "Ophtalmology", se suman a las evidencias ya sabidas de que los consumidores de pescado tienden a registrar tasas más bajas de DMAE.


El estudio también respalda la teoría de que los ácidos grasos omega 3, abundantes en el salmón o el atún( en la fotografía ) tienen beneficios. El estudio fue realizado por el equipo de Bonnielin Swenor, perteneciente al grupo de investigación en Oftalomología de la Universidad norteamericana de Johns Hopkins.

23 July 2010

European Society of Cardiology launches heart-friendly cookery book‏

The European Society of Cardiology (ESC) today announces the upcoming launch of its all-new European Cook Book. Bringing together recipes created by leading cardiologists from across its membership, the aim of this high quality book is to demonstrate that a diverse, heart-friendly diet can be achieved without compromising on taste. The ESC strongly endorses a healthy and balanced diet as an effective means of lowering the risks from conditions such as hypertension, diabetes and coronary artery disease.

“The European Cook Book is absolutely a key part of our mission to reduce the burden of cardiovascular disease in Europe”, explains Professor Roberto Ferrari, President of the ESC. “Prevention of heart disease through education programmes about what to eat is a key part of our strategy. But while most people know the benefits of a good diet, it can still be very hard to persuade them to adopt new habits. Many mistakenly believe that healthy eating has to mean a bland and repetitive diet that could never excite their taste buds. After trying many of the recipes in this book myself, however, I can say that this is definitely not the case!”

This is a cookery book with a difference. The conventional part comprises 200-plus pages laid out as 43 menus of national recipes representing the unique cultural and culinary heritage of member and affiliate countries. The rich diversity of the ESC covering mainland Europe, the Mediterranean basin and beyond has strongly influenced the recipes – all of which have been submitted by heart specialists from each country. A professional chef and nutritionist has tested and adapted the recipes to create dishes that are heart-friendly yet very enjoyable.

But this cookery book also contains a really vital message to all Europeans about how the right diet choices can positively help avoid cardiovascular disease. The introductory pages give an easy-to-understand overview of the heart itself and explain its role as the engine of life. There are sections that discuss the major heart disease topics along with symptoms and treatments, and an excellent reference table for all cooks to use that indicates healthier alternatives to everyday ingredients such as oils, fats and seasoning.

Professor Ferrari is hopeful that the ESC’s European Cook Book will become a great success. “We set out to offer new thinking for the preparation of meals, not just in the context of blindly following these specific recipes but in becoming familiar with alternative, healthy ingredients and cooking methods that become part of a routine. It’s also very exciting to imagine people experimenting with completely new dishes from different cultures, and knowing that they are reducing their exposure to heart health risks while still enjoying the social benefits of a shared and tasty meal.”

The European Cook Book will be formally launched on the first day of ESC Congress 2010 to be held in Stockholm between 28 August and 1 September. Information about the book and ways to order can be found at the ESC website. The online price will be EUR 23, but it will be available for the special price of EUR 20 at the Congress, with each sale resulting in a donation to the European Heart for Children charity.

Descubren la causa de la celiaquía


Científicos del Instituto de Investigación Médica Walter&Eliza Hall, en Melbourne (Australia) han descubierto tres compuestos clave en el gluten --una proteína que se encuentra en el trigo, centeno y cebada-- que son los causantes de la enfermedad celiaca, según los resultados de la investigación que publica en su último número la revista 'Science Translational Medicine'.

En este trastorno digestivo, el gluten provoca una reacción en el sistema inmune que daña la capa que recubre el intestino delgado dificultando su capacidad para absorber nutrientes y, si la enfermedad no se detecta, se puede provocar una severa desnutrición.

Actualmente no existen tratamientos para esta patología, por lo que la única solución es que los pacientes dejen de comer productos con gluten aunque, según los autores de esta investigación, el hallazgo podría conducir al desarrollo de nuevos tratamientos y métodos de diagnóstico.

"El Santo Grial de la investigación de la enfermedad celíaca ha sido identificar los componentes tóxicos del gluten", ha explicado a la BBC el doctor Bob Anderson, autor de la investigación, que ha durado nueve años y en la que han participado más de 200 pacientes de Melbourne y Oxford (Reino Unido).

Según explica Anderson, se pidió a los voluntarios que comieran pan de trigo y centeno, y cebada hervida. Seis días después se tomaron muestras de sangre de los pacientes para medir su respuesta inmune a miles de distintos componentes del gluten.

De este modo, las pruebas identificaron 90 péptidos que causaban algún tipo de reacción inmune, pero se encontró que tres de éstos eran particularmente tóxicos. Según el profesor Anderson "estos tres componentes están involucrados en la mayoría de las respuestas inmunes del gluten que se observan en las personas que sufren enfermedad celiaca".

--EL PRIMER PASO PARA UNA FUTURA VACUNA

El nuevo hallazgo ya está siendo utilizado por una compañía de biotecnología para desarrollar una inmunoterapia que permita insensibilizar a los pacientes celíacos a los efectos tóxicos del gluten, y consistiría en exponer al enfermo a pequeñas cantidades de los tres péptidos tóxicos.

La primera fase de los ensayos clínicos fue completada en junio pasado y se espera tener los resultados en los próximos meses. Sarah Sleet, presidenta ejecutiva de la organización Coeliac Uk, afirma que el hallazgo potencialmente podría conducir a una vacuna contra la enfermedad.

"Es una pieza importante en el rompecabezas, pero todavía se necesitan más investigaciones, así que no deberíamos esperar una solución práctica en los próximos años", explica a la BBC, en declaraciones recogidas por Europa Press.

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud